We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies

Dlp3.0

DLPA Research

Mostly mechanism / observationalModerate safety

4 peer-reviewed studies

What the evidence says

Mostly mechanism / observational

Most DLPA studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.

Most evidence is from mixed-quality randomised trials published 1979–2015 with a typical study size of 181 participants.

Based on 4 studies · 1 RCT · 221 total participants

Confidence

Low

By outcome

Depression & moodPossible mild mood support as a catecholamine precursor — anchored on a single old, placebo-free comparison trial · 2-4 weeks (uncertain)
Too few graded studies1 study

Older research base

Newest study from 2015

197919972015

1Open-Labeln=181 · medium study1994

L-Phe may have a place in the treatment of vitiligo and its role merits further investigation.

Siddiqui AH, Stolk LM, Bhaggoe R, Hu R, Schutgens RB, Westerhof W. · Dermatology (1994)

Open trial (149 patients, 18 months) plus a small double-blind trial (32 patients, 6 months) of oral L-phenylalanine plus UVA
Repigmentation up to 77% (open) and 60% (double-blind) was observed
Higher L-Phe doses did not improve results; optimal dose appeared below 50 mg/kg/day

View source

2Review2015

L-phenylalanine is among the most commonly studied complementary agents for vitiligo, used as monotherapy or with phototherapy.

Cohen BE, Elbuluk N, Mu EW, Orlow SJ. · Am J Clin Dermatol (2015)

Narrative review of alternative systemic vitiligo treatments including L-phenylalanine
Summarizes proposed mechanism (melanin-synthesis substrate) and supportive but limited evidence with UVA
Does not address mood or pain indications

View source

3RCTn=40 · small study1979

DL-phenylalanine might have substantial antidepressant properties, although methodological considerations warrant careful interpretation.

Beckmann H, Athen D, Olteanu M, Zimmer R. · Arch Psychiatr Nervenkr (1979)

40 depressed patients randomized to DL-phenylalanine (150-200 mg/day) or imipramine for 30 days; 27 completed
No statistically significant difference between DLPA and imipramine on the Hamilton Depression Scale
No placebo arm, so an absolute antidepressant effect cannot be established

View source

4Review2000

DL-phenylalanine often appears to potentiate pain relief in patients receiving opiates, possibly via up-regulation of the endogenous analgesia system.

Russell AL, McCarty MF. · Med Hypotheses (2000)

Hypothesis/mechanism paper, not a controlled trial
Proposes D-phenylalanine acts as an enkephalinase inhibitor to prolong endorphin/enkephalin action
Based on clinical impression rather than randomized data

View source

View in Research Library

DLPA Research

Mostly mechanism / observational

L-phenylalanine and UVA irradiation in the treatment of vitiligo.

Alternative Systemic Treatments for Vitiligo: A Review.

DL-phenylalanine versus imipramine: a double-blind controlled study.

DL-phenylalanine markedly potentiates opiate analgesia - an example of nutrient/pharmaceutical up-regulation of the endogenous analgesia system.